AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: MRAL
Report Date: 2026-04-07
Full Report: https://amaly.io/stock/MRAL

EXECUTIVE SUMMARY
------------------
Compliance Status: UNDER_REVIEW
Quality Rating: B
Description: This report assesses the Shariah compliance of MRAL, a clinical-stage biotechnology company focused on oncology. Due to insufficient financial data availability, key ratios cannot be computed, leading to an overall UNDER_REVIEW status. Business activities in healthcare appear permissible, with no identified non-compliant revenues. Index inclusions remain unknown, and ESG factors show low risk with strong governance. Investors should await further disclosures for definitive compliance.

Primary Compliance Concerns:
- Insufficient data to calculate debt ratio (threshold: 30%)
- Insufficient data to calculate liquidity ratio (threshold: 30%)
- Insufficient data to calculate interest income ratio (threshold: 5%)
- Insufficient data to calculate non-permissible income ratio (threshold: 5%)

Purification Requirement: 0.00%
Index Inclusion: Inclusion status unknown across all major Shariah indices due to data limitations

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 0.0%
Liquidity Ratio: 0.0%
Interest Income Ratio: 0.0%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: INCLUDED
MSCI Islamic: INCLUDED
DJIM: INCLUDED
FTSE Shariah: INCLUDED
Total: 4 of 4
Last Verified: Unknown

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-19T12:00:00Z

---
Full interactive report: https://amaly.io/stock/MRAL
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.